{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:24:26Z","timestamp":1785795866800,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11060-019-03253-5","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T10:02:45Z","timestamp":1564567365000},"page":"529-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Initial biopsy and early re-resection practices in the treatment of glioblastoma among AANS\/CNS tumor section surgeons"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6196-7691","authenticated-orcid":false,"given":"Rebecca B.","family":"Baron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi A.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos G.","family":"Hadjipanayis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"key":"3253_CR1","volume-title":"Glioblastoma","author":"C Fernandes","year":"2017","unstructured":"Fernandes C, Costa A, Osorio L, Lago RC, Linhares P, Carvalho B, Caeiro C (2017) Current standards of care in glioblastoma therapy. In: De Vleeschouwer S (ed) Glioblastoma. Codon Publications, Brisbane"},{"key":"3253_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-017-2564-z","volume":"135","author":"ME van Linde","year":"2017","unstructured":"van Linde ME, Brahm CG, de Witt Hamer PC, Reijneveld JC, Bruynzeel AM, Vandertop WP, van de Ven PM, Wagemakers M, van der Weide HL, Enting RH, Walenkamp AM (2017) Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. J Neuro-Oncol 135:183\u2013192","journal-title":"J Neuro-Oncol"},{"key":"3253_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. \n                    https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"3253_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","volume":"2","author":"TJ Brown","year":"2016","unstructured":"Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M (2016) Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2:1460\u20131469. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2016.1373","journal-title":"JAMA Oncol"},{"key":"3253_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1227\/neu.0000000000000629","volume":"76","author":"W Stummer","year":"2015","unstructured":"Stummer W (2015) Response to journal club: 5-aminolevulinic acid-derived tumor fluorescence: the diagnostic accuracy of visible fluorescence qualities as corroborated by spectrometry and histology and postoperative imaging. Neurosurgery 76:230\u2013231. \n                    https:\/\/doi.org\/10.1227\/neu.0000000000000629","journal-title":"Neurosurgery"},{"key":"3253_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3978\/j.issn.2305-5839.2015.05.10","volume":"3","author":"RM Young","year":"2015","unstructured":"Young RM, Jamshidi A, Davis G, Sherman JH (2015) Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med 3:121. \n                    https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.05.10","journal-title":"Ann Transl Med"},{"key":"3253_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/brainsci8010005","volume":"8","author":"A Haj","year":"2018","unstructured":"Haj A, Doenitz C, Schebesch K-M, Ehrensberger D, Hau P, Putnik K, Riemenschneider M, Wendl C, Gerken M, Pukrop TJ (2018) Extent of resection in newly diagnosed glioblastoma: impact of a specialized neuro-oncology care center. Brain Sci 8:5","journal-title":"Brain Sci"},{"key":"3253_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","volume":"7","author":"W Stummer","year":"2006","unstructured":"Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J, Oncology A-GSGJTl (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392\u2013401","journal-title":"Lancet Oncol"},{"key":"3253_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","volume":"115","author":"N Sanai","year":"2011","unstructured":"Sanai N, Polley M-Y, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosug 115:3\u20138","journal-title":"J Neurosug"},{"key":"3253_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/neuonc\/3.3.193","volume":"3","author":"RJ Jackson","year":"2001","unstructured":"Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, Wildrick DM, Sawaya R (2001) Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-Oncology 3:193\u2013200. \n                    https:\/\/doi.org\/10.1093\/neuonc\/3.3.193","journal-title":"Neuro-Oncology"},{"key":"3253_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3171\/jns.2006.104.2.233","volume":"104","author":"GF Woodworth","year":"2006","unstructured":"Woodworth GF, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD (2006) Frameless image-guided stereotactic brain biopsy procedure: diagnostic yield, surgical morbidity, and comparison with the frame-based technique. J Neurosug 104:233\u2013237","journal-title":"J Neurosug"},{"key":"3253_CR12","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.clineuro.2013.05.019","volume":"115","author":"T Reithmeier","year":"2013","unstructured":"Reithmeier T, Lopez W, Doostkam S, Machein M, Pinsker M, Trippel M, Nikkhah GJ (2013) Intraindividual comparison of histopathological diagnosis obtained by stereotactic serial biopsy to open surgical resection specimen in patients with intracranial tumours. Clin Neurol Neurosurg 115:1955\u20131960","journal-title":"Clin Neurol Neurosurg"},{"key":"3253_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/00006123-199805000-00054","volume":"42","author":"R Sawaya","year":"1998","unstructured":"Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi W-M, WiIdrick DM (1998) Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosugery 42:1044\u20131055","journal-title":"Neurosugery"},{"key":"3253_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0090-3019(03)00048-X","volume":"59","author":"MJ McGirt","year":"2003","unstructured":"McGirt MJ, Villavicencio AT, Bulsara KR, Friedman AH (2003) MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen. Surg Neurol 59:277\u2013281 (discussion 281\u2013272)","journal-title":"Surg Neurol"},{"key":"3253_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.wneu.2017.04.053","volume":"103","author":"M Rapp","year":"2017","unstructured":"Rapp M, Baernreuther J, Turowski B, Steiger H-J, Sabel M, Kamp MA (2017) Recurrence pattern analysis of primary glioblastoma. World Neurosug 103:733\u2013740","journal-title":"World Neurosug"},{"key":"3253_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11060-017-2625-3","volume":"136","author":"DA Donoho","year":"2018","unstructured":"Donoho DA, Wen T, Babadjouni RM, Schwartzman W, Buchanan IA, Cen SY, Zada G, Mack WJ, Attenello FJ (2018) Predictors of 30-and 90-day readmission following craniotomy for malignant brain tumors: analysis of nationwide data. J Neuro-Oncol 136:87\u201394","journal-title":"J Neuro-Oncol"},{"key":"3253_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/nop\/npu008","volume":"1","author":"M Nu\u00f1o","year":"2014","unstructured":"Nu\u00f1o M, Ly D, Mukherjee D, Ortega A, Black KL, Patil CG (2014) Quality of surgical care and readmission in elderly glioblastoma patients. Neuro-Oncol Pract 1:33\u201339","journal-title":"Neuro-Oncol Pract"},{"key":"3253_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1227\/NEU.0000000000000243","volume":"74","author":"M Nu\u00f1o","year":"2013","unstructured":"Nu\u00f1o M, Ly D, Ortega A, Sarmiento JM, Mukherjee D, Black KL, Patil CG (2013) Does 30-day readmission affect long-term outcome among glioblastoma patients? Neurosurgery 74:196\u2013205","journal-title":"Neurosurgery"},{"key":"3253_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0749-3797(00)00258-0","volume":"20","author":"SE Kellerman","year":"2001","unstructured":"Kellerman SE, Herold J (2001) Physician response to surveys. A review of the literature. Am J Prevent Med 20:61\u201367","journal-title":"Am J Prevent Med"},{"key":"3253_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fonc.2015.00055","volume":"5","author":"NR Parker","year":"2015","unstructured":"Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR (2015) Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol 5:55. \n                    https:\/\/doi.org\/10.3389\/fonc.2015.00055","journal-title":"Front Oncol"},{"key":"3253_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","volume":"95","author":"M Lacroix","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190\u2013198. \n                    https:\/\/doi.org\/10.3171\/jns.2001.95.2.0190","journal-title":"J Neurosurg"},{"key":"3253_CR22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3171\/2015.5.JNS142087","volume":"124","author":"YM Li","year":"2016","unstructured":"Li YM, Suki D, Hess K, Sawaya RJ (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 124:977\u2013988","journal-title":"J Neurosurg"},{"key":"3253_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/03007995.2016.1275935","volume":"33","author":"P Li","year":"2017","unstructured":"Li P, Qian R, Niu C, Fu X (2017) Impact of intraoperative MRI-guided resection on resection and survival in patient with gliomas: a meta-analysis. Curr Med Res Opin 33:621\u2013630. \n                    https:\/\/doi.org\/10.1080\/03007995.2016.1275935","journal-title":"Curr Med Res Opin"},{"key":"3253_CR24","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/s1470-2045(11)70130-9","volume":"12","author":"PL Kubben","year":"2011","unstructured":"Kubben PL, ter Meulen KJ, Schijns OE, ter Laak-Poort MP, van Overbeeke JJ, van Santbrink H (2011) Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol 12:1062\u20131070. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(11)70130-9","journal-title":"Lancet Oncol"},{"key":"3253_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11060-004-9603-2","volume":"71","author":"F Duffner","year":"2005","unstructured":"Duffner F, Ritz R, Freudenstein D, Weller M, Dietz K, Wessels J (2005) Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX. J Neuro-Oncol 71:107\u2013111. \n                    https:\/\/doi.org\/10.1007\/s11060-004-9603-2","journal-title":"J Neuro-Oncol"},{"key":"3253_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-019-03109-y","volume":"141","author":"CG Hadjipanayis","year":"2019","unstructured":"Hadjipanayis CG, Stummer W, Sheehan JP (2019) 5-ALA fluorescence-guided surgery of CNS tumors. J Neuro-Oncol 141:477\u2013478. \n                    https:\/\/doi.org\/10.1007\/s11060-019-03109-y","journal-title":"J Neuro-Oncol"},{"key":"3253_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1227\/neu.0000000000000929","volume":"77","author":"CG Hadjipanayis","year":"2015","unstructured":"Hadjipanayis CG, Widhalm G, Stummer W (2015) What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? Neurosurgery 77:663\u2013673. \n                    https:\/\/doi.org\/10.1227\/neu.0000000000000929","journal-title":"Neurosurgery"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-019-03253-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T23:22:56Z","timestamp":1596064976000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-019-03253-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1007\/s11060-019-03253-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,31]]},"assertion":[{"value":"11 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RBB has no disclosures to report. RAK has no disclosures to report. Constantinos Hadjipanayis is a consultant for NX Development Corp. (NXDC) and Synaptive Medical Inc. He receives royalties from NXDC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}